Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846416 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT01846416 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 138 participants.
The verdict
NCT01846416, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles until disease progression. Eligible participants will be categorized in to three groups as follows: 1. Participants with no prior chemotherapy for advanced disease; 2. Participants who progress during or following a prior-platinum based chemotherapy regimen for advanced disease (2L+participants); 3. Participants who are 2L+ and previously treated for brain metastases.
Interventions
- DRUG Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2013-05-30 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846416
The ClinicalTrials.gov registry entry for NCT01846416 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody is the first listed.
NCT01846416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01846416 about?
NCT01846416 is a clinical study titled "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]". This multicenter, single-arm study will evaluate the efficacy and safety of atezolizumab (MPDL3280A) in participants with PD-L1-positive locally advanced or metastatic NSCLC. Participants will receive an intravenous (IV) dose of 1200 milligrams (mg) atezolizumab (MPDL3280A) on Day 1 of 21-day cycles...
What is the current status of trial NCT01846416?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2013-05-30. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT01846416?
The interventions under investigation include: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody (DRUG).
Who is sponsoring clinical trial NCT01846416?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.